Physician

Mohamed Omar Atwaibi, M.D

According to 2025 Medicare claims, Mohamed Atwaibi, M.D (NPI: 1558590067) practices nephrology in the Elmira, NY market, with the plurality of this provider's patient population coming from Chemung, NY. This provider's primary affiliated billing organization is ARNOT MEDICAL SERVICES PLLC (NPI: 1427326768; TIN: 45-3800308) and primary practice location at 14830-2267. Atwaibi is affiliated with the Cayuga Health Partners (ACO ID: A3195), participating under the MSSP model.

Atwaibi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 272 traditional Medicare patients, billed 1,004 HCPCS/CPT codes, and received $135,608 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 797 prescription claims across 188 beneficiaries totaling $233,476 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 155 claims. Open Payments data shows 3 records totaling $33. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $51,102 and ending at $135,608. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $22,923 and ending at $233,476. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	152	580	$51,102
2016	228	702	$65,247
2017	354	1,599	$147,671
2018	368	1,723	$185,295
2019	361	1,133	$131,371
2020	384	1,148	$120,288
2021	369	1,260	$191,924
2022	308	1,112	$159,150
2023	286	984	$126,952
2024	272	1,004	$135,608

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	55	316	$22,923
2016	64	335	$37,596
2017	125	478	$177,510
2018	145	732	$210,591
2019	157	1,153	$265,160
2020	140	806	$155,862
2021	140	714	$134,513
2022	136	628	$125,545
2023	157	676	$156,490
2024	188	797	$233,476

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	51	$1,612
2019	N/R	71	$2,329
2020	N/R	96	$3,745
2021	N/R	72	$3,074
2022	N/R	108	$3,637
2023	N/R	128	$3,165
2024	N/R	155	$3,420

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	65	234	$267
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	50	87	$222
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	37	37	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	128	193	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	78	341	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	12	480	$53,265
Farxiga	Dapagliflozin Propanediol	15	1,290	$21,568
Lokelma	Sodium Zirconium Cyclosilicate	16	840	$14,414
Sevelamer Carbonate	Sevelamer Carbonate	30	2,140	$12,498
Prosol	Parenteral Amino Acid 20% No.1	66	458	$12,162

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	35	$1,309
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	51	$903
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	38	$464
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	20	$375
J7500	Azathioprine, oral, 50 mg	N	N/R	11	$368

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$33	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohamed Omar Atwaibi, M.D?

Tedicare shows public-source Medicare data for Mohamed Omar Atwaibi, M.D (NPI 1558590067), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohamed Omar Atwaibi, M.D have ACO affiliation data?

Mohamed Omar Atwaibi, M.D is shown with ACO affiliation data for Cayuga Health Partners (MSSP, ACO ID A3195).

What billing organization is linked to Mohamed Omar Atwaibi, M.D?

Mohamed Omar Atwaibi, M.D is linked to ARNOT MEDICAL SERVICES PLLC (billing NPI 1427326768) in the available physician profile data.

Does Mohamed Omar Atwaibi, M.D have Open Payments data?

Mohamed Omar Atwaibi, M.D has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.